drugset / Trial / NCT07274059
Allogeneic UCB-derived CAR-T for SLE
Phase 0
Recruiting
48 enrolled
Chengdu Ucello Biotechnology Co., Ltd.
The General Hospital of Western Theater Command · collabYancheng Third People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to learn if allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) targeting CD19 and BCMA works to treat refractory SLE in adults. It will also learn about the safety and efficacy of the UCAR-T cell product.
Timeline
- Start
- 2025-03-26
- Primary completion
- 2035-12-31
- Completion
- 2037-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA | Cell therapy | — | Intravenous |